Table 1.

Baseline characteristics.

CharacteristicNonenhancing glioma (n = 22)Enhancing glioma (n = 30)Glioma overall (n = 52)Non-gliomaa (n = 41)
Age in years47.0 (16–73)b40.1 (18–59)42.5 (16–73)b57.0 (28–89)
Sex
 Male8 (36.4)18 (60.0)26 (50.0)14 (34.1)
 Female14 (63.6)12 (40.0)26 (50.0)27 (65.9)
ECOG performance status score at baseline
 07 (31.8)11 (36.7)18 (34.6)10 (24.4)
 113 (59.1)18 (60.0)31 (59.6)28 (68.3)
 201 (3.3)1 (1.9)3 (7.3)
 Unknown2 (9.1)2 (3.8)
IDH mutationc
IDH120 (90.9)28 (93.3)48 (92.3)27 (65.9)
IDH21 (4.5)2 (6.7)3 (5.8)14 (34.1)
WHO tumor grade at screening
 Grade II17 (77.3)8 (26.7)25 (48.1)
 Grade III5 (22.7)17 (56.7)22 (42.3)
 Grade IV04 (13.3)4 (7.7)
 Unknownc01 (3.3)1 (1.9)
1p19q
 Intact9 (40.9)11 (36.7)20 (38.5)
 Deleted8 (36.4)8 (26.7)16 (30.8)
 Unknown5 (22.7)11 (36.7)16 (30.8)
Prior surgery only7 (31.8)4 (13.3)11 (21.2)2 (4.9)
Prior radiation therapy
 Yes8 (36.4)22 (73.3)30 (57.7)9 (22.0)
Prior systemic therapy
 Yes14 (63.6)25 (83.3)39 (75.0)38 (92.7)
  Number of prior systemic therapies2 (1–4)2 (1–6)2 (1–6)2 (1–7)
  • Note: Data are median (range) or n (%) unless otherwise stated.

  • Abbreviation: ECOG, Eastern Cooperative Oncology Group.

  • aSee Supplementary Fig. S1 for the included non-glioma solid tumors.

  • bA 16-year-old patient was enrolled in the study through an eligibility waiver.

  • cOne patient with nonenhancing glioma did not have any prior biopsy; grade of tumor is therefore unknown. IDH mutation was presumed by the investigator as evidenced by consistent 2-HG elevation by magnetic resonance spectroscopy.